



TOMÁS J. ARAGÓN, M.D., Dr.P.H.
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

March 19, 2025

Linda Ward
Laboratory Director
San Bernadino County Public Health Laboratory
150 East Holt Blvd.,
Ontario, CA 91761

Authority:
Section 311(c)(1) of the Public
Health Service Act (42 USC
243(c)(1))

ELC SHARP
Award Number - ELCPHLSHARP-06

American Rescue Plan Act of 2021

Dear Ms. Ward:

This letter covers the ELC Sharp funding through July 31, 2026. California's current surveillance for AR pathogens relies on limited testing performed by local Public Health Laboratories (PHLs), the CDPH Microbial Diseases Laboratory (MDL), and the Washington Regional ARLN laboratory. This ELC Strengthening HAI/AR Program Capacity (SHARP) funding will support expansion of antimicrobial resistance (AR) surveillance in California via screening activities for carbapenemase-producing organisms (CPOs) and *Candida auris*, as well as supporting additional capacity for other optional activities including Whole Genome Sequencing (WGS) for HAI/AR pathogens and establishing capacity for AST of *Neisseria gonorrhoeae*.

CDPH will allocate \$3,816,604.77 to 14 local PHLs that have proposed to provide additional testing for HAI/AR pathogens to build capacity for the AR laboratory network in California. Funding for SHARP activities is covered for the period beginning August 1, 2021 to July 31, 2026. The California Department of Public Health (CDPH) is allocating **\$178,597.82 to San Bernardino County Public Health Laboratory**.

Funding:

The ELC funding term for this project is August 1, 2021 to July 31, 2026. CDPH will evaluate spending at the local level in August 2023 and will consider options for possible redirection of funds at that time.

Allowable Costs:



Approved funding was based on the initial proposals that were submitted by your laboratory, availability of funds, and alignment of proposed activities with surveillance and testing priorities.

For a detailed listing of allowable costs and activities, please refer to the funding guidance document, Attachment X.

Unallowable Costs:

The funding associated with the SHARP grant cannot be used for the following costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body.
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body.

Submission Requirements:

Complete the attached Workplan and Spend Plan by **06/17/2022** and submit to CDPH utilizing the ELENOR System. See *Attachments 1 and 2*. Your Agency should consider the following when developing your Workplan and Spend Plan:

- If hiring staff from these project funds, develop approximate goals and metrics regarding diversity of staff hired and equity and inclusion activities. Report on progress against those measures will be required.
- Reasonable Milestones and Achieve By dates that accomplish the project mission. Progress on milestones will be evaluated quarterly.
- Spend plan within your proposed budget that specifically support the activities in your workplan and project proposal.

Reporting Requirements:

As a subrecipient of ELC SHARP funding, it will be required to submit reporting documents and requested data. For your convenience, your Contract Manager will issue reminders as these dates get closer through the *Enhanced Laboratory Emergency Network Operations and Response* platform (ELENOR). Training will be provided on the ELENOR system should any county not currently be utilizing it.

1. Quarterly progress reports on status of timelines, goals, and objectives.
2. Performance metrics that will be required by CDC for reporting and/or defined by the CDPH. Due dates will be provided once they are made available.
 - Applicable data may include numbers of screening and/or confirmatory tests performed and breakdown of results for CPO pathogens (including species tested if performing confirmatory testing) and *C. auris*, number of HAI/AR isolates sequenced (WGS) and sequence data uploaded to NCBI, number of *N. gonorrhoeae* isolates submitted for AST (with related result breakdown), and number of tests sent to MDL or the Regional ARLN in Washington.
 - Additional metrics may be requested.

Progress reports must be submitted to CDPH through the ELENOR system following the schedule below. Note, if your workplan or spend plan is under review by CDPH and has not been approved by the progress report due date, you are still required to submit your progress report to CDPH.

Year/Quarter	Reporting Period	Due Date
Year 1/Q4	May 1, 2022 – July 31, 2022	August 15, 2022
Year 1/Q5	August 1, 2022 – October 31, 2022	November 15, 2022
Year 1/Q6	November 1, 2022 – January 31, 2023	February 15, 2023
Year 1/Q7	February 1, 2023 – April 30, 2023	May 15, 2023
Year 1 /Q8	May 1, 2022 – July 31, 2022	August 15, 2023
Year 2 /Q1	August 1, 2023 – October 31, 2023	November 15, 2023
Year 2 /Q2	November 1, 2023 – January 31, 2024	February 15, 2024
Year 2/Q3	February 1, 2024 – April 30, 2024	May 15, 2024
Year 2/Q4 Final	May 1, 2024 – July 31, 2024	August 15, 2024

Reimbursement/Invoicing:

CDPH will reimburse your Agency upon receipt of invoice. In order to receive your reimbursements, please complete and submit your invoice(s) through the ELENOR system. See Attachment 3-Invoice.

1. Payment: Upon receipt of invoice, CDPH will reimburse your Agency for 100% of your total expenditure per invoice.

2. Your Agency must maintain supporting documentation for any expenditures invoiced to CDPH against this source of funding. Documentation should be readily available in the event of an audit or upon request from CDPH. Documentation should be maintained onsite for five years.

Thank you for the time your Agency has and will continue to invest in this initiative to build a strong surveillance network in California for AR pathogens. If you have any questions or need further clarification, please reach out to:
katemcpherson@internationalrespondersystems.com

Sincerely,

Paul B. Kimsey Ph.D.

Paul B. Kimsey, Ph.D.
Deputy Director
California Department of Public Health
California State Public Health Laboratory Director
850 Marina Bay Pkwy
Richmond, CA. 94804
510-412-5846-phone
510-412-5848-fax

Attachments

Attachment 1: Workplan and Progress Report
Attachment 2: Spend Plan and Expenditure Report
Attachment 3: Invoice Template
Attachment 4: HAI Sharp Funding Guidance